Study for early breast cancer patients with low-risk genes
Treatments studied
Part of Cancer clinical trials.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (about ages 19–80).
- Your breast cancer is invasive, hormone receptor–positive (ER+ and/or PR+), and HER2-negative (HER2-).
- Your lymph node workup is pN0 or pN1 (not pN2/pN3).
- Your tumor is at least 0.5 cm, and you had surgery intended to cure (not just a biopsy).
- Your tumor testing shows “genomic low risk,” and you agree to genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how genetic tests like Oncotype DX or Mammaprint are used to guide treatment decisions for people with early-stage, hormone receptor-positive (HR+) and HER2-negative breast cancer. It aims to help doctors choose between hormone therapy alone or chemotherapy plus hormone therapy.
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
This study looks at how planned hormone (endocrine) treatment, the menstrual cycle, and lab markers from the tumor may help doctors choose the best treatment for early-stage, hormone-receptor–positive, HER2-negative breast cancer. It may help personalize decisions, including what to do before surgery.
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
This study observes how doctors treat early breast cancer and what outcomes patients have. It's for people with hormone receptor-positive, HER2-negative breast cancer that hasn't spread to many lymph nodes.
Hear when a new Early Hormone Receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.